Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/03/2020 07:59 PDT] APTX Expected to Trade Down After Bearish Patterns Develop
• [03/31/2020 10:10 PDT] Aptinyx Inc. (NASDAQ:APTX), Up By 100.00% ($2.05) From $2.050 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [03/24/2020 08:21 PDT] APTX Expected to Trade Up After Bullish Patterns Develop
• [03/20/2020 07:56 PDT] APTX Expected to Trade Up After Bullish Patterns Develop
• [03/13/2020 13:20 PDT] Aptinyx Inc. (NASDAQ:APTX), Down By 100.00% ($2.41) From $2.410 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [03/11/2020 07:52 PDT] APTX Expected to Trade Down After Bearish Patterns Develop
• [02/24/2020 08:09 PST] APTX Expected to Trade Up After Bullish Patterns Develop